Led by researcher Dr. Guangdi Wang, Xavier University spinout startup Zenopharm has received a federal Small Business Innovation Research grant from the National Institutes of Health for nearly $300,000. The grant from the National Cancer Institute will help fund pre-clinical studies for the team’s novel breast cancer therapeutic. This orally-administered drug has shown promise in early studies in treating breast cancer and preventing recurrence more effectively and with fewer side effects than the injected treatment currently available. The Zenopharm team hopes to progress to clinical trials after completing these IND-enabling studies. Zenopharm has been working with the Center’s Commercialization team on strategy development and is a past BioChallenge pitch competition finalist.